NUVATION BIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.68 USD | +2.29% |
|
+3.08% | +77.48% |
| Apr. 17 | RBC Raises Price Target on Nuvation Bio to $5 From $4, Keeps Outperform, Speculative Risk | MT |
| Apr. 10 | Nuvation Bio Closes Acquisition of AnHeart Therapeutics | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 825K | Capitalization | 704M |
|---|---|---|---|---|---|
| Net income 2024 * | -101M | Net income 2025 * | -163M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 853 x |
| P/E ratio 2024 * |
-7.58
x | P/E ratio 2025 * |
-5.33
x | Employees | 51 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.17% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.29% | ||
| 1 week | +3.08% | ||
| Current month | -26.37% | ||
| 1 month | -6.94% | ||
| 3 months | +55.81% | ||
| 6 months | +139.29% | ||
| Current year | +77.48% |
1 week
2.51
2.79
1 month
2.514.16
Current year
1.434.16
1 year
0.954.16
3 years
0.9515.23
5 years
0.9515.23
10 years
0.9515.23
| Managers | Title | Age | Since |
|---|---|---|---|
David Hung
FOU | Founder | 66 | 18-03-19 |
Moses Makunje
DFI | Director of Finance/CFO | 46 | 20-06-30 |
Dong Fang Liu
CTO | Chief Tech/Sci/R&D Officer | 54 | 22-07-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Hung
FOU | Founder | 66 | 18-03-19 |
Kim Blickenstaff
BRD | Director/Board Member | 71 | 19-07-31 |
Kathryn Falberg
BRD | Director/Board Member | 63 | 20-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 2.68 | +2.29% | 637,370 |
| 24-04-25 | 2.62 | -1.50% | 642,571 |
| 24-04-24 | 2.66 | -0.75% | 1,280,789 |
| 24-04-23 | 2.68 | 0.00% | 885,607 |
| 24-04-22 | 2.68 | +3.08% | 1,086,344 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm EDT
More quotes
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.62
USD
Average target price
6.6
USD
Spread / Average Target
+151.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +77.48% | 688M | |
| +1.51% | 42.59B | |
| +8.57% | 40.65B | |
| +49.22% | 40.57B | |
| -12.36% | 26.77B | |
| +8.92% | 24.81B | |
| -25.13% | 18.17B | |
| +29.17% | 12.05B | |
| -3.12% | 11.7B | |
| +6.35% | 11.1B |
- Stock Market
- Equities
- NUVB Stock
